AMT-151

Developed for: endometrial clear cell adenocarcinoma · endometrial endometrioid adenocarcinoma · endometrial serous adenocarcinoma · lung adenocarcinoma · malignant pleural mesothelioma · ovarian clear cell adenocarcinoma · ovarian endometrioid adenocarcinoma · ovarian mucinous adenocarcinoma
+2 more
· pancreatic ductal adenocarcinoma · triple-negative breast carcinoma
Investigated by: Multitude Therapeutics Inc. · Tigermed Consulting Co., Ltd

today NCT05498597 · Ph 1

2023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05498597	Jan 2023 → Jan 2024	endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial serous adenocarcinoma, lung adenocarcinoma +6	Multitude Therapeutics Inc.	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	AMT-151	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05498597 ↗
Route	Intravenous	“Administered intravenously” NCT05498597 ↗